Lunai Bioworks (LNAI) Proxy filing summary

Executive summary

• Special meeting of stockholders rescheduled to May 8, 2026, to address key corporate actions.

• Completion of the acquisition of Neurobridge IP Holdings Incorporated and issuance of Series B Convertible Preferred Stock as merger consideration.

• Actions taken to achieve compliance with Nasdaq continued listing requirements following the merger.

• Forward-looking statements address compliance with Nasdaq rules, fair-value treatment of Series B Preferred Stock, and continued listing.

Voting matters and shareholder proposals

• Proposals include the Reverse Split Proposal and other matters detailed in the definitive proxy statement.

• Board recommends voting FOR all proposals, including the Reverse Split Proposal.

• Proxies previously submitted remain effective unless revoked.

Board of directors and corporate governance

• Directors and executive officers are participants in the proxy solicitation, with interests disclosed in proxy and annual filings.